Vox lays out why plans are dropping weight loss drugs after coverage hit about two in three employers, with surveys showing more cuts coming in 2027.
Recap by typeshit. Full story at Vox.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
Dr Leana Wen, Robert Gebelhoff and Dominic Pino talk through the range of side effects that can come with GLP-1 drugs such as Ozempic.
A brief post suggests cases from other countries could hint at how serious unapproved drug use might get in the US, with a link to international reports.
Loading…